Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Sonnet Biotherapeutics Holdings Inc
SONN
Consumer Cyclical
Biotechnology
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is...
designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:SONN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 11, 2025 9:15am
New Press Release - Sonnet Releases Virtual Investor "What This Means" Segment
- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)- Watch the "What This Means" video herePRINCETON, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Sonnet...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 04, 2025 8:40am
New Press Release - Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221)Topline safety, cytokine, and efficacy data suggest a strong potential for clinical benefit using the current...
read article.
(476)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 14, 2025 11:52am
SONN.... N.L.O.D $10.10
It ain't done yet....lower share price to come ; ) Wait for it
(476)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 14, 2025 11:13am
SONN.....Major PB from H.O.D
now at $10.42 from $18.72 Support at $8.77
(476)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 14, 2025 11:05am
SONN.....This is being diluted "Big Time"
Wouldn't touch this now
(243)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Jul 14, 2025 6:20am
Buy buddy buy.
Otherwise FOMO for you fellas out there today
(476)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 14, 2025 6:13am
SONN...ripping on NR pre-market
No position....unfortunately
(243)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Jul 07, 2025 6:17am
Buy buddy buy because it's taking off this morning.
Otherwise FOMO anyway
(476)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 02, 2025 12:26pm
SONN....runner on volume and no News ; )
Here is why.....do be a Greater Fool ....JMHO...High to day was over $3 https://www.sec.gov/Archives/edgar/data/1106838/000164117225017478/form8-k.htm
(10)
•••
MikeTester
X
Post by
MikeTester
on Jan 24, 2025 1:56am
Sonnet BioTherapeutics: Advancing Innovative Immunotherapies
Digging into SONN. Looks like an interesting play in immunotherapies. Their F H AB platform seems unique - basically attaching drugs to albumin to improve delivery and extend activity. Lead asset SON
...more
(476)
•••
Iseneschal
X
Comment by
Iseneschal
on Jan 23, 2025 6:26am
RE:SONN....now that the "dust has settled"
Yesterdays pop to over $2 was due to this patent news : ALBUMIN BINDING DOMAIN FUSION PROTEINS - European Patent Office - EP 3583125 B1 On watch to see if there is sh price continuation
(476)
•••
Iseneschal
X
Post by
Iseneschal
on Jan 22, 2025 11:28am
SONN....now that the "dust has settled"
SONN on watch list Currently trading at $1.60 and generating NR's Unit Financing completed at $2.23 Cheers !
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 23, 2024 9:20am
New Press Release - Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next CEO Corner segment has been published on the Company’s website.As part...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 17, 2024 8:50am
New Press Release - Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing agreement to support initiation of a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN) Multiple value-driving milestones...
read article.
(476)
•••
Iseneschal
X
Comment by
Iseneschal
on Dec 09, 2024 8:07pm
RE:SONN....S1A filed 11/04/24
I gave you all fair warning that there was a P.O being set up....here's the news: Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
Pinnacle Extends Gold-Silver Mineralized Horizon to Almost 500 Metres at Historic La Dura Mine
Eshbal Signs Definitive Agreement to Acquire Majority Interest in NYC-Based Dare to Be Different Foods
Allied Critical Metals Confirms Ultra High-Grade Tungsten Zone at Borralha
SALT: quietly powering industries, keeping roads safe, and even shaping the global economy
The first public copper company permitted to drill in Argentina’s newly opened Mendoza province